Truist Financial’s Celldex Therapeutics CLDX Stock Holding History

Truist Financial’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,768	Closed	-$257K	–	2753
2021 Q3	$257K	Buy	+4,768	New	+$224K	﹤0.01%	2438

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Truist Financial's CLDX Position: Q4 2021 in Review

Truist Financial sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 4,768 shares — an estimated $257K sold.

Truist Financial first reported a position in CLDX in Q3 2021 and held it in 1 quarter. The position peaked at $257K in Q3 2021. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

Truist Financial reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
Truist Financial sold 4,768 Celldex Therapeutics shares in Q4 2021, an estimated $257K.
Truist Financial first reported a position in Celldex Therapeutics in Q3 2021 and held it in 1 quarter.
Truist Financial's Celldex Therapeutics position peaked at $257K in Q3 2021.
180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.